Erzofri Extended-release Injection
Product Images NDC 72526-105

Product Visual Gallery

This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Erzofri Extended-release (NDC 72526-105). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Shandong Luye Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Erzofri 01)

An instructional illustration showing components for injection administration including a 22-gauge by 1.5-inch needle with a gray hub, a 23-gauge by 1-inch needle with a blue hub, and a prefilled syringe with a tip cap. The diagram labels the needle hubs and syringe tip.*

FDA Label Image

Image (Erzofri 02)

An illustration showing the injection site for intramuscular administration on the upper arm. It depicts a shaded area on the deltoid muscle where the injection should be given, indicated by a large black arrow pointing to the site.*

FDA Label Image

Image (Erzofri 03)

An instructional illustration showing the proper intramuscular injection site on the upper arm and buttock area. The diagram highlights the shoulder and upper back region with arrows indicating the injection locations.*

FDA Label Image

Image (Erzofri 04)

An instructional diagram showing hands peeling or removing a backing from an adhesive patch or label, possibly demonstrating how to prepare packaging or apply a component related to the product.*

FDA Label Image

Image (Erzofri 05)

An instructional line drawing showing a hand holding a syringe. The fingers are positioned to push the plunger down, indicated by arrows pointing up and down, demonstrating the correct technique for injecting or administering an intramuscular injection.*

FDA Label Image

Image (Erzofri 06)

An instructional illustration showing one hand holding a syringe barrel while the other hand twists the syringe plunger, indicating how to prepare or adjust the syringe prior to injection.*

FDA Label Image

Image (Erzofri 07)

An instructional illustration depicting hands preparing a syringe for injection by peeling off a protective covering from the needle area. The image is related to the administration of Erzofri extended-release paliperidone palmitate injection.*

FDA Label Image

Image (Erzofri 08)

An instructional illustration showing a hand removing a cap from a syringe prefilled with Erzofri extended-release paliperidone palmitate injection. The image depicts proper handling and preparation of the intramuscular injection prior to administration.*

FDA Label Image

Image (Erzofri 09)

An instructional illustration showing hands preparing an injection by holding a vial and syringe, with an arrow indicating the direction of liquid being drawn up into the syringe.*

FDA Label Image

Image (Erzofri 10)

An illustration showing the deltoid muscle location on a person's upper arm, indicated by a darkened area and an arrow pointing to it. This diagram depicts the injection site for intramuscular administration of the medication.*

FDA Label Image

Image (Erzofri 11)

An instructional illustration showing the gluteal intramuscular injection site on the human body. It depicts an arm and the lower back area with an arrow pointing to the gluteal region, indicating where the injection should be administered.*

FDA Label Image

Image (Erzofri 12)

An instructional illustration showing a hand holding a syringe for intramuscular injection. The image highlights the proper grip and positioning of the syringe, associated with the administration of Erzofri extended-release (paliperidone palmitate) injection.*

FDA Label Image

Image (Erzofri 13)

An instructional illustration showing safe disposal of needles and syringes into a biohazard sharps container. One image shows a needle being inserted into the container; the other shows a capped syringe being disposed of, emphasizing proper intramuscular injection waste management.*

FDA Label Image

Image (Erzofri 14)

An instructional line drawing showing a hand gripping and twisting the cap of a syringe containing an injectable medication. The diagram depicts the correct technique for opening the syringe prior to intramuscular administration.*

FDA Label Image

Image (Erzofri 15)

An instructional diagram showing the assembly of a syringe for injection. The image depicts a hand inserting or attaching a needle to the syringe body with a plunger visible on the right side.*

FDA Label Image

Chemical Structure (Erzofri 16)

Chemical structure diagram of paliperidone palmitate, the active ingredient in Erzofri extended-release injection by Shandong Luye Pharmaceutical Co., Ltd.*

FDA Label Image

Figure 1 (Erzofri 17)

A chart illustrating paliperidone fold change and 90% confidence intervals for area under the curve (AUC) and maximum concentration (Cmax) when co-administered with CYP2D6 inhibitor paroxetine, CYP3A4 inducer carbamazepine, and divalproex sodium ER. The x-axis shows change relative to reference without interacting drug, with values ranging from 0.0 to 2.0.*

FDA Label Image

Figure 2 (Erzofri 18)

A chart depicting the fold change and 90% confidence interval of paliperidone pharmacokinetic parameters (AUC and Cmax) in different conditions: renal impairment (mild, moderate, severe), hepatic impairment (moderate), and age groups (18-64 vs over 65 years). The x-axis shows the change relative to reference, ranging from 0 to 6.*

FDA Label Image

Figure 3 (Erzofri 19)

A Kaplan-Meier plot showing the estimated percent of subjects with relapse over time in days since randomization. The graph compares two groups: placebo (dashed line, N=156) and once-a-month paliperidone palmitate extended-release injectable suspension (solid line, N=156). The placebo group shows a higher relapse percentage compared to the paliperidone palmitate group.*

FDA Label Image

Figure 4 (Erzofri 20)

A Kaplan-Meier curve chart depicting the estimated percent of subjects with treatment failure over time (days since randomization) comparing oral antipsychotic treatment (dashed line, N=218) versus once-a-month paliperidone palmitate extended-release injectable suspension (solid line, N=226). The graph shows treatment failure trends up to approximately 450 days.*

FDA Label Image

Figure 5 (Erzofri 21)

A line graph showing the estimated percent of subjects with relapse over time in days since randomization. It compares placebo with once-a-month paliperidone palmitate extended-release injectable suspension, illustrating lower relapse rates in the treatment group throughout the study duration up to 450 days.*

FDA Label Image

Principal Display Panel (39 mg/0.25 mL Syringe Kit)

Erzofri extended-release injectable suspension 39 mg/0.25 mL prefilled syringe label for intramuscular injection by Shandong Luye Pharmaceutical Co., Ltd. The packaging includes directions to use entire contents of the syringe for single use only, storage conditions, and a list of active and inactive ingredients including paliperidone palmitate.*

FDA Label Image

Principal Display Panel (78 mg/0.5 mL Syringe Kit)

Label for Erzofri extended-release injectable suspension, paliperidone palmitate, 78 mg/0.5 mL intramuscular injection by Shandong Luye Pharmaceutical Co., Ltd. The label shows dosage strength, single-use vial content, intramuscular use instructions, active ingredient, inactive ingredients, storage conditions, and kit contents including a prefilled syringe and needles.*

FDA Label Image

Principal Display Panel (117 mg/0.75 mL Syringe Kit)

Erzofri extended-release injectable suspension 117 mg/0.75 mL by Shandong Luye Pharmaceutical Co., Ltd. The label shows the product as a prefilled syringe for intramuscular injection, highlighting the need for healthcare professional administration and single use. The packaging includes active and inactive ingredients and storage instructions.*

FDA Label Image

Principal Display Panel (156 mg/mL Syringe Kit)

Erzofri extended-release injectable suspension 156 mg/mL (paliperidone palmitate) label for intramuscular injection by Shandong Luye Pharmaceutical Co., Ltd. The label includes usage instructions, active and inactive ingredients, and states single-use prefilled syringe with 1 mL containing 156 mg paliperidone palmitate. Packaging highlights storage conditions and kit contents including needles.*

FDA Label Image

Principal Display Panel (234 mg/1.5 mL Syringe Kit)

Erzofri extended-release injectable suspension label with a strength of 234 mg/1.5 mL of paliperidone palmitate for intramuscular injection. The label includes dosage form details, usage instructions for single use, and manufacturer information, Shandong Luye Pharmaceutical Co., Ltd. The design features a multicolor gradient with blue, purple, and green accents.*

FDA Label Image

Principal Display Panel (351 mg/2.25 mL Syringe Kit)

Erzofri extended-release injectable suspension 351 mg/2.25 mL intramuscular injection, containing paliperidone palmitate. The label shows a single-dose prefilled syringe kit by Shandong Luye Pharmaceutical Co., Ltd, featuring usage instructions, active and inactive ingredients, storage conditions, and regulatory information including NDC 72526-110-11 and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.